Disease-modifying drugs (DMARDs), Psoriatic arthritis, Real-world evidence

被引：1
|
作者：
Song, J. [1 ,2 ]
Abe, C. [1 ,2 ]
Banefelt, J. [3 ]
Rieem-Dun, A. [3 ]
Willems, D. [1 ]
Morup, M. [1 ]
Taieb, V. [1 ]
Lindberg, I. [1 ]
Welby, S. [1 ]
机构：
[1] UCB Pharma, Braine Lalleud, Belgium
[2] Karolinska Inst, Stockholm, Sweden
[3] Quantify Res, Stockholm, Sweden
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Disease-modifying drugs (DMARDs); Psoriatic arthritis; Real-world evidence;
D O I：
10.1136/annrheumdis-2023-eular.3573
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1785 / 1786
页数：2
相关论文
共 50 条
  • [1] BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PSORIATIC ARTHRITIS: A REAL-WORLD COHORT OF 439 PATIENTS
    Letarouilly, J-G
    Salmon, J. -H.
    Coquerelle, P.
    Goeb, V.
    Guyot, M. -H.
    Houvenagel, E.
    Maury, F.
    Marguerie, L.
    Morel, G.
    Baudens, G.
    Solau-Gervais, E.
    Ramdane, N.
    Flipo, R. -M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 373 - 373
  • [2] REAL-WORLD USAGE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH PSORIATIC ARTHRITIS IN GERMANY
    Song, J.
    Anjohrin, S.
    Abe, C.
    Banefelt, J.
    Rieem, Dun A.
    Picker, N.
    Kromer, D.
    Fuchs, A.
    Hahn, P.
    Welby, S.
    VALUE IN HEALTH, 2023, 26 (12) : S305 - S305
  • [3] Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan
    Erik, Lars
    Soliman, Ahmed
    Nunag, Dominic
    Lippe, Ralph
    Davis, Matthew
    Kishimoto, Mitsumasa
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4444 - 4445
  • [4] Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
    Huss, Viking
    Bower, Hannah
    Hellgren, Karin
    Frisell, Thomas
    Askling, Johan
    ARTIS grp
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (07) : 911 - 919
  • [5] PERSISTENCE OF MONOTHERAPY OR COMBINATION THERAPY WITH DISEASE-MODIFYING AGENTS IN PATIENTS WITH PSORIATIC ARTHRITIS IN A REAL-WORLD SETTING
    Saidane, O.
    Sellami, M.
    Barhoumi, R.
    Ben Tekaya, A.
    Ajlani, H.
    Tekaya, R.
    Mahmoud, I.
    Abdelmoula, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 612 - 612
  • [6] PERSISTENCE OF MONOTHERAPY OR COMBINATION THERAPY WITH DISEASE-MODIFYING AGENTS IN PATIENTS WITH PSORIATIC ARTHRITIS IN A REAL-WORLD SETTING
    Mease, P. J.
    Accortt, N. A.
    Rebello, S.
    Etzel, C.
    Harrison, R. W.
    Aras, G. A.
    Gharaibeh, M. M. F.
    Greenberg, J. D.
    Collier, D. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 612 - 612
  • [7] Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
    Rosenberg, Vered
    Amital, Howard
    Chodick, Gabriel
    Faccin, Freddy
    Gendelman, Omer
    DRUGS & AGING, 2024, 41 (08) : 685 - 697
  • [8] Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study
    Philipp Sewerin
    Kathrin Borchert
    Dominic Meise
    Matthias Schneider
    Jörg Mahlich
    Rheumatology and Therapy, 2021, 8 : 483 - 497
  • [9] Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis
    Marguerie, L
    Flipo, RM
    Grardel, B
    Beaurain, D
    Duquesnoy, B
    Delcambre, B
    JOINT BONE SPINE, 2002, 69 (03) : 275 - 281
  • [10] Real-World Treatment Effectiveness of Disease-Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis
    Jin, Yinzhu
    Liu, Jun
    Desai, Rishi J.
    Kim, Seoyoung C.
    ACR OPEN RHEUMATOLOGY, 2023, 5 (11) : 571 - 580
12345